Answers are grounded in this paper and cite their sources.
A “second-generation process” for the enantioselective synthesis of l -neopentylglycine has been developed, realizing the first whole cell-catalyzed approach to this pharmaceutically interesting, bulky amino acid. The synthesis of this nonnatural amino acid proceeds highly efficiently via a reductive amination of the corresponding α-keto acid in the presence of a recombinant whole cell catalyst, bearing a leucine dehydrogenase and formate dehydrogenase. The desired l -neopentylglycine was obtained with >95% conversion and a high enantioselectivity of >99% ee at substrate concentrations of up to 88 g/L.
No takes yet. Share an insight, caveat, or question.
Gröger et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: